Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058"

NCT01187810 is registered in ClinicalTrials.gov with South Plains Oncology Consortium as lead sponsor.

NCT NCT01187810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01187810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058"
Lead sponsor
South Plains Oncology Consortium
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2010
Completion date
April 30, 2018
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myelogenous leukemia, non-hodgkin's lymphoma